nodes	percent_of_prediction	percent_of_DWPC	metapath
Levonorgestrel—AR—scrotum—colon cancer	0.0659	0.274	CbGeAlD
Levonorgestrel—SRD5A1—renal system—colon cancer	0.0185	0.077	CbGeAlD
Levonorgestrel—PGR—blood vessel—colon cancer	0.0135	0.0559	CbGeAlD
Levonorgestrel—SRD5A1—liver—colon cancer	0.0113	0.047	CbGeAlD
Levonorgestrel—ESR1—blood vessel—colon cancer	0.0105	0.0437	CbGeAlD
Levonorgestrel—PGR—epithelium—colon cancer	0.00655	0.0272	CbGeAlD
Levonorgestrel—PGR—smooth muscle tissue—colon cancer	0.00631	0.0262	CbGeAlD
Levonorgestrel—ESR1—embryo—colon cancer	0.00628	0.0261	CbGeAlD
Levonorgestrel—AR—epithelium—colon cancer	0.00522	0.0217	CbGeAlD
Levonorgestrel—ESR1—epithelium—colon cancer	0.00512	0.0213	CbGeAlD
Levonorgestrel—SHBG—bone marrow—colon cancer	0.0051	0.0212	CbGeAlD
Levonorgestrel—PGR—lymphoid tissue—colon cancer	0.00504	0.021	CbGeAlD
Levonorgestrel—AR—smooth muscle tissue—colon cancer	0.00503	0.0209	CbGeAlD
Levonorgestrel—ESR1—smooth muscle tissue—colon cancer	0.00494	0.0205	CbGeAlD
Levonorgestrel—SHBG—vagina—colon cancer	0.00488	0.0203	CbGeAlD
Levonorgestrel—AR—renal system—colon cancer	0.00484	0.0201	CbGeAlD
Levonorgestrel—ESR1—renal system—colon cancer	0.00475	0.0197	CbGeAlD
Levonorgestrel—PGR—vagina—colon cancer	0.0044	0.0183	CbGeAlD
Levonorgestrel—SHBG—liver—colon cancer	0.00412	0.0171	CbGeAlD
Levonorgestrel—AR—lymphoid tissue—colon cancer	0.00402	0.0167	CbGeAlD
Levonorgestrel—AR—digestive system—colon cancer	0.00397	0.0165	CbGeAlD
Levonorgestrel—ESR1—lymphoid tissue—colon cancer	0.00395	0.0164	CbGeAlD
Levonorgestrel—ESR1—digestive system—colon cancer	0.0039	0.0162	CbGeAlD
Levonorgestrel—AR—vagina—colon cancer	0.00351	0.0146	CbGeAlD
Levonorgestrel—ESR1—vagina—colon cancer	0.00344	0.0143	CbGeAlD
Levonorgestrel—CYP19A1—liver—colon cancer	0.00334	0.0139	CbGeAlD
Levonorgestrel—AR—liver—colon cancer	0.00296	0.0123	CbGeAlD
Levonorgestrel—ESR1—liver—colon cancer	0.0029	0.0121	CbGeAlD
Levonorgestrel—PGR—lymph node—colon cancer	0.00285	0.0118	CbGeAlD
Levonorgestrel—CYP3A4—renal system—colon cancer	0.00265	0.011	CbGeAlD
Levonorgestrel—CYP19A1—lymph node—colon cancer	0.00256	0.0106	CbGeAlD
Levonorgestrel—AR—lymph node—colon cancer	0.00227	0.00942	CbGeAlD
Levonorgestrel—ESR1—lymph node—colon cancer	0.00223	0.00925	CbGeAlD
Levonorgestrel—CYP3A4—digestive system—colon cancer	0.00217	0.00904	CbGeAlD
Levonorgestrel—CYP3A4—liver—colon cancer	0.00162	0.00673	CbGeAlD
Levonorgestrel—Migraine—Capecitabine—colon cancer	0.00154	0.00336	CcSEcCtD
Levonorgestrel—Pharyngitis—Fluorouracil—colon cancer	0.00153	0.00335	CcSEcCtD
Levonorgestrel—Vaginal infection—Methotrexate—colon cancer	0.00151	0.00331	CcSEcCtD
Levonorgestrel—Cardiac disorder—Irinotecan—colon cancer	0.0015	0.00327	CcSEcCtD
Levonorgestrel—Mediastinal disorder—Vincristine—colon cancer	0.00149	0.00327	CcSEcCtD
Levonorgestrel—Mood swings—Capecitabine—colon cancer	0.00148	0.00323	CcSEcCtD
Levonorgestrel—Alopecia—Vincristine—colon cancer	0.00146	0.0032	CcSEcCtD
Levonorgestrel—Immune system disorder—Irinotecan—colon cancer	0.00146	0.00319	CcSEcCtD
Levonorgestrel—Mediastinal disorder—Irinotecan—colon cancer	0.00145	0.00318	CcSEcCtD
Levonorgestrel—Mental disorder—Vincristine—colon cancer	0.00145	0.00317	CcSEcCtD
Levonorgestrel—Neoplasm—Methotrexate—colon cancer	0.00145	0.00317	CcSEcCtD
Levonorgestrel—Bladder pain—Methotrexate—colon cancer	0.00145	0.00317	CcSEcCtD
Levonorgestrel—Arrhythmia—Irinotecan—colon cancer	0.00144	0.00315	CcSEcCtD
Levonorgestrel—Dry skin—Capecitabine—colon cancer	0.00143	0.00313	CcSEcCtD
Levonorgestrel—Alopecia—Irinotecan—colon cancer	0.00142	0.00312	CcSEcCtD
Levonorgestrel—Breast disorder—Capecitabine—colon cancer	0.00141	0.00308	CcSEcCtD
Levonorgestrel—Back pain—Vincristine—colon cancer	0.00139	0.00305	CcSEcCtD
Levonorgestrel—Flatulence—Irinotecan—colon cancer	0.00138	0.00303	CcSEcCtD
Levonorgestrel—Arrhythmia—Fluorouracil—colon cancer	0.00138	0.00302	CcSEcCtD
Levonorgestrel—Alopecia—Fluorouracil—colon cancer	0.00136	0.00299	CcSEcCtD
Levonorgestrel—Back pain—Irinotecan—colon cancer	0.00136	0.00297	CcSEcCtD
Levonorgestrel—Abdominal distension—Capecitabine—colon cancer	0.00136	0.00297	CcSEcCtD
Levonorgestrel—Muscle spasms—Irinotecan—colon cancer	0.00135	0.00295	CcSEcCtD
Levonorgestrel—Asthma—Capecitabine—colon cancer	0.00135	0.00295	CcSEcCtD
Levonorgestrel—Influenza—Capecitabine—colon cancer	0.00135	0.00295	CcSEcCtD
Levonorgestrel—Erythema—Fluorouracil—colon cancer	0.00134	0.00294	CcSEcCtD
Levonorgestrel—Anaemia—Vincristine—colon cancer	0.00133	0.00292	CcSEcCtD
Levonorgestrel—Sweating increased—Capecitabine—colon cancer	0.00131	0.00287	CcSEcCtD
Levonorgestrel—Anaemia—Irinotecan—colon cancer	0.0013	0.00284	CcSEcCtD
Levonorgestrel—Bronchitis—Capecitabine—colon cancer	0.0013	0.00284	CcSEcCtD
Levonorgestrel—Vertigo—Vincristine—colon cancer	0.00129	0.00283	CcSEcCtD
Levonorgestrel—Vertigo—Irinotecan—colon cancer	0.00126	0.00276	CcSEcCtD
Levonorgestrel—Dysuria—Capecitabine—colon cancer	0.00126	0.00276	CcSEcCtD
Levonorgestrel—Syncope—Irinotecan—colon cancer	0.00126	0.00275	CcSEcCtD
Levonorgestrel—Upper respiratory tract infection—Capecitabine—colon cancer	0.00125	0.00274	CcSEcCtD
Levonorgestrel—Hypertension—Vincristine—colon cancer	0.00124	0.00272	CcSEcCtD
Levonorgestrel—Anaemia—Fluorouracil—colon cancer	0.00124	0.00272	CcSEcCtD
Levonorgestrel—Loss of consciousness—Irinotecan—colon cancer	0.00123	0.0027	CcSEcCtD
Levonorgestrel—Myalgia—Vincristine—colon cancer	0.00123	0.00269	CcSEcCtD
Levonorgestrel—Weight increased—Capecitabine—colon cancer	0.00123	0.00269	CcSEcCtD
Levonorgestrel—Cough—Irinotecan—colon cancer	0.00122	0.00268	CcSEcCtD
Levonorgestrel—Weight decreased—Capecitabine—colon cancer	0.00122	0.00267	CcSEcCtD
Levonorgestrel—Hypertension—Irinotecan—colon cancer	0.00121	0.00265	CcSEcCtD
Levonorgestrel—Pneumonia—Capecitabine—colon cancer	0.00121	0.00265	CcSEcCtD
Levonorgestrel—Infestation NOS—Capecitabine—colon cancer	0.0012	0.00263	CcSEcCtD
Levonorgestrel—Infestation—Capecitabine—colon cancer	0.0012	0.00263	CcSEcCtD
Levonorgestrel—Depression—Capecitabine—colon cancer	0.0012	0.00262	CcSEcCtD
Levonorgestrel—Discomfort—Irinotecan—colon cancer	0.00118	0.00258	CcSEcCtD
Levonorgestrel—Oedema—Vincristine—colon cancer	0.00118	0.00257	CcSEcCtD
Levonorgestrel—Infection—Vincristine—colon cancer	0.00117	0.00256	CcSEcCtD
Levonorgestrel—Urinary tract infection—Capecitabine—colon cancer	0.00117	0.00256	CcSEcCtD
Levonorgestrel—Nervous system disorder—Vincristine—colon cancer	0.00115	0.00252	CcSEcCtD
Levonorgestrel—Oedema—Irinotecan—colon cancer	0.00115	0.00251	CcSEcCtD
Levonorgestrel—Chest pain—Fluorouracil—colon cancer	0.00114	0.0025	CcSEcCtD
Levonorgestrel—Myalgia—Fluorouracil—colon cancer	0.00114	0.0025	CcSEcCtD
Levonorgestrel—Infection—Irinotecan—colon cancer	0.00114	0.00249	CcSEcCtD
Levonorgestrel—Hyperhidrosis—Vincristine—colon cancer	0.00114	0.00249	CcSEcCtD
Levonorgestrel—Discomfort—Fluorouracil—colon cancer	0.00113	0.00247	CcSEcCtD
Levonorgestrel—Shock—Irinotecan—colon cancer	0.00113	0.00247	CcSEcCtD
Levonorgestrel—Nervous system disorder—Irinotecan—colon cancer	0.00112	0.00246	CcSEcCtD
Levonorgestrel—Anorexia—Vincristine—colon cancer	0.00112	0.00245	CcSEcCtD
Levonorgestrel—Hyperhidrosis—Irinotecan—colon cancer	0.00111	0.00242	CcSEcCtD
Levonorgestrel—Mood swings—Methotrexate—colon cancer	0.0011	0.00241	CcSEcCtD
Levonorgestrel—Oedema—Fluorouracil—colon cancer	0.0011	0.0024	CcSEcCtD
Levonorgestrel—Anorexia—Irinotecan—colon cancer	0.00109	0.00239	CcSEcCtD
Levonorgestrel—Infection—Fluorouracil—colon cancer	0.00109	0.00239	CcSEcCtD
Levonorgestrel—Haemoglobin—Capecitabine—colon cancer	0.00108	0.00237	CcSEcCtD
Levonorgestrel—Rhinitis—Capecitabine—colon cancer	0.00108	0.00237	CcSEcCtD
Levonorgestrel—Haemorrhage—Capecitabine—colon cancer	0.00108	0.00236	CcSEcCtD
Levonorgestrel—Nervous system disorder—Fluorouracil—colon cancer	0.00108	0.00235	CcSEcCtD
Levonorgestrel—Hypoaesthesia—Capecitabine—colon cancer	0.00107	0.00235	CcSEcCtD
Levonorgestrel—Musculoskeletal discomfort—Vincristine—colon cancer	0.00107	0.00235	CcSEcCtD
Levonorgestrel—Pharyngitis—Capecitabine—colon cancer	0.00107	0.00234	CcSEcCtD
Levonorgestrel—Urinary tract disorder—Capecitabine—colon cancer	0.00107	0.00233	CcSEcCtD
Levonorgestrel—Insomnia—Vincristine—colon cancer	0.00106	0.00233	CcSEcCtD
Levonorgestrel—Connective tissue disorder—Capecitabine—colon cancer	0.00106	0.00232	CcSEcCtD
Levonorgestrel—Urethral disorder—Capecitabine—colon cancer	0.00106	0.00231	CcSEcCtD
Levonorgestrel—Breast disorder—Methotrexate—colon cancer	0.00105	0.0023	CcSEcCtD
Levonorgestrel—Anorexia—Fluorouracil—colon cancer	0.00105	0.00229	CcSEcCtD
Levonorgestrel—Visual impairment—Capecitabine—colon cancer	0.00104	0.00228	CcSEcCtD
Levonorgestrel—Insomnia—Irinotecan—colon cancer	0.00104	0.00227	CcSEcCtD
Levonorgestrel—Decreased appetite—Vincristine—colon cancer	0.00102	0.00224	CcSEcCtD
Levonorgestrel—Dyspnoea—Irinotecan—colon cancer	0.00102	0.00223	CcSEcCtD
Levonorgestrel—Erythema multiforme—Capecitabine—colon cancer	0.00102	0.00223	CcSEcCtD
Levonorgestrel—Somnolence—Irinotecan—colon cancer	0.00102	0.00223	CcSEcCtD
Levonorgestrel—Gastrointestinal disorder—Vincristine—colon cancer	0.00102	0.00222	CcSEcCtD
Levonorgestrel—Fatigue—Vincristine—colon cancer	0.00101	0.00222	CcSEcCtD
Levonorgestrel—Eye disorder—Capecitabine—colon cancer	0.00101	0.00221	CcSEcCtD
Levonorgestrel—Dyspepsia—Irinotecan—colon cancer	0.00101	0.00221	CcSEcCtD
Levonorgestrel—Pain—Vincristine—colon cancer	0.00101	0.0022	CcSEcCtD
Levonorgestrel—Constipation—Vincristine—colon cancer	0.00101	0.0022	CcSEcCtD
Levonorgestrel—Asthma—Methotrexate—colon cancer	0.001	0.0022	CcSEcCtD
Levonorgestrel—Cardiac disorder—Capecitabine—colon cancer	0.001	0.00219	CcSEcCtD
Levonorgestrel—Musculoskeletal discomfort—Fluorouracil—colon cancer	0.000999	0.00219	CcSEcCtD
Levonorgestrel—Decreased appetite—Irinotecan—colon cancer	0.000996	0.00218	CcSEcCtD
Levonorgestrel—Insomnia—Fluorouracil—colon cancer	0.000992	0.00217	CcSEcCtD
Levonorgestrel—Gastrointestinal disorder—Irinotecan—colon cancer	0.000989	0.00216	CcSEcCtD
Levonorgestrel—Fatigue—Irinotecan—colon cancer	0.000987	0.00216	CcSEcCtD
Levonorgestrel—Constipation—Irinotecan—colon cancer	0.000979	0.00214	CcSEcCtD
Levonorgestrel—Pain—Irinotecan—colon cancer	0.000979	0.00214	CcSEcCtD
Levonorgestrel—Dyspnoea—Fluorouracil—colon cancer	0.000978	0.00214	CcSEcCtD
Levonorgestrel—Somnolence—Fluorouracil—colon cancer	0.000975	0.00213	CcSEcCtD
Levonorgestrel—Immune system disorder—Capecitabine—colon cancer	0.000974	0.00213	CcSEcCtD
Levonorgestrel—Mediastinal disorder—Capecitabine—colon cancer	0.000972	0.00213	CcSEcCtD
Levonorgestrel—Dyspepsia—Fluorouracil—colon cancer	0.000966	0.00211	CcSEcCtD
Levonorgestrel—Arrhythmia—Capecitabine—colon cancer	0.000964	0.00211	CcSEcCtD
Levonorgestrel—Gastrointestinal pain—Vincristine—colon cancer	0.000962	0.0021	CcSEcCtD
Levonorgestrel—Decreased appetite—Fluorouracil—colon cancer	0.000953	0.00209	CcSEcCtD
Levonorgestrel—Alopecia—Capecitabine—colon cancer	0.000953	0.00209	CcSEcCtD
Levonorgestrel—Gastrointestinal disorder—Fluorouracil—colon cancer	0.000947	0.00207	CcSEcCtD
Levonorgestrel—Mental disorder—Capecitabine—colon cancer	0.000945	0.00207	CcSEcCtD
Levonorgestrel—Erythema—Capecitabine—colon cancer	0.000939	0.00206	CcSEcCtD
Levonorgestrel—Malnutrition—Capecitabine—colon cancer	0.000939	0.00206	CcSEcCtD
Levonorgestrel—Dysuria—Methotrexate—colon cancer	0.000938	0.00205	CcSEcCtD
Levonorgestrel—Pain—Fluorouracil—colon cancer	0.000938	0.00205	CcSEcCtD
Levonorgestrel—Gastrointestinal pain—Irinotecan—colon cancer	0.000936	0.00205	CcSEcCtD
Levonorgestrel—Upper respiratory tract infection—Methotrexate—colon cancer	0.000933	0.00204	CcSEcCtD
Levonorgestrel—Body temperature increased—Vincristine—colon cancer	0.00093	0.00203	CcSEcCtD
Levonorgestrel—Abdominal pain—Vincristine—colon cancer	0.00093	0.00203	CcSEcCtD
Levonorgestrel—Flatulence—Capecitabine—colon cancer	0.000925	0.00203	CcSEcCtD
Levonorgestrel—Back pain—Capecitabine—colon cancer	0.000908	0.00199	CcSEcCtD
Levonorgestrel—Abdominal pain—Irinotecan—colon cancer	0.000905	0.00198	CcSEcCtD
Levonorgestrel—Body temperature increased—Irinotecan—colon cancer	0.000905	0.00198	CcSEcCtD
Levonorgestrel—Muscle spasms—Capecitabine—colon cancer	0.000903	0.00198	CcSEcCtD
Levonorgestrel—Pneumonia—Methotrexate—colon cancer	0.0009	0.00197	CcSEcCtD
Levonorgestrel—Infestation NOS—Methotrexate—colon cancer	0.000895	0.00196	CcSEcCtD
Levonorgestrel—Infestation—Methotrexate—colon cancer	0.000895	0.00196	CcSEcCtD
Levonorgestrel—Depression—Methotrexate—colon cancer	0.000892	0.00195	CcSEcCtD
Levonorgestrel—Urticaria—Fluorouracil—colon cancer	0.000871	0.00191	CcSEcCtD
Levonorgestrel—Anaemia—Capecitabine—colon cancer	0.000868	0.0019	CcSEcCtD
Levonorgestrel—Body temperature increased—Fluorouracil—colon cancer	0.000867	0.0019	CcSEcCtD
Levonorgestrel—Hypersensitivity—Vincristine—colon cancer	0.000866	0.0019	CcSEcCtD
Levonorgestrel—Vertigo—Capecitabine—colon cancer	0.000844	0.00185	CcSEcCtD
Levonorgestrel—Hypersensitivity—Irinotecan—colon cancer	0.000844	0.00185	CcSEcCtD
Levonorgestrel—Asthenia—Vincristine—colon cancer	0.000844	0.00185	CcSEcCtD
Levonorgestrel—Syncope—Capecitabine—colon cancer	0.000842	0.00184	CcSEcCtD
Levonorgestrel—Palpitations—Capecitabine—colon cancer	0.00083	0.00182	CcSEcCtD
Levonorgestrel—Loss of consciousness—Capecitabine—colon cancer	0.000825	0.00181	CcSEcCtD
Levonorgestrel—Asthenia—Irinotecan—colon cancer	0.000822	0.0018	CcSEcCtD
Levonorgestrel—Cough—Capecitabine—colon cancer	0.00082	0.00179	CcSEcCtD
Levonorgestrel—Hypertension—Capecitabine—colon cancer	0.000811	0.00177	CcSEcCtD
Levonorgestrel—Hypersensitivity—Fluorouracil—colon cancer	0.000808	0.00177	CcSEcCtD
Levonorgestrel—Haemoglobin—Methotrexate—colon cancer	0.000807	0.00177	CcSEcCtD
Levonorgestrel—ESR1—FOXM1 transcription factor network—MYC—colon cancer	0.000807	0.00268	CbGpPWpGaD
Levonorgestrel—ESR1—Aryl Hydrocarbon Receptor—NRAS—colon cancer	0.000806	0.00267	CbGpPWpGaD
Levonorgestrel—Diarrhoea—Vincristine—colon cancer	0.000805	0.00176	CcSEcCtD
Levonorgestrel—Haemorrhage—Methotrexate—colon cancer	0.000803	0.00176	CcSEcCtD
Levonorgestrel—CYP3A4—Metapathway biotransformation—CHST5—colon cancer	0.000801	0.00266	CbGpPWpGaD
Levonorgestrel—Chest pain—Capecitabine—colon cancer	0.0008	0.00175	CcSEcCtD
Levonorgestrel—Myalgia—Capecitabine—colon cancer	0.0008	0.00175	CcSEcCtD
Levonorgestrel—Pharyngitis—Methotrexate—colon cancer	0.000797	0.00174	CcSEcCtD
Levonorgestrel—Anxiety—Capecitabine—colon cancer	0.000797	0.00174	CcSEcCtD
Levonorgestrel—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—colon cancer	0.000794	0.00174	CcSEcCtD
Levonorgestrel—Urinary tract disorder—Methotrexate—colon cancer	0.000793	0.00174	CcSEcCtD
Levonorgestrel—ESR1—LKB1 signaling events—MYC—colon cancer	0.000792	0.00263	CbGpPWpGaD
Levonorgestrel—Discomfort—Capecitabine—colon cancer	0.00079	0.00173	CcSEcCtD
Levonorgestrel—Urethral disorder—Methotrexate—colon cancer	0.000787	0.00172	CcSEcCtD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—ABCB1—colon cancer	0.000786	0.00261	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—CA7—colon cancer	0.000786	0.00261	CbGpPWpGaD
Levonorgestrel—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—colon cancer	0.000785	0.00261	CbGpPWpGaD
Levonorgestrel—Diarrhoea—Irinotecan—colon cancer	0.000784	0.00172	CcSEcCtD
Levonorgestrel—AR—Regulation of nuclear beta catenin signaling and target gene transcription—CCND1—colon cancer	0.00078	0.00259	CbGpPWpGaD
Levonorgestrel—Dizziness—Vincristine—colon cancer	0.000778	0.0017	CcSEcCtD
Levonorgestrel—Pruritus—Fluorouracil—colon cancer	0.000776	0.0017	CcSEcCtD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—BUB1B—colon cancer	0.000776	0.00258	CbGpPWpGaD
Levonorgestrel—Visual impairment—Methotrexate—colon cancer	0.000774	0.00169	CcSEcCtD
Levonorgestrel—CYP19A1—Integrated Breast Cancer Pathway—BAX—colon cancer	0.000773	0.00256	CbGpPWpGaD
Levonorgestrel—AR—Regulation of nuclear beta catenin signaling and target gene transcription—CTNNB1—colon cancer	0.000772	0.00256	CbGpPWpGaD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—TYMS—colon cancer	0.000772	0.00256	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling mediated by p38-alpha and p38-beta—TP53—colon cancer	0.000767	0.00255	CbGpPWpGaD
Levonorgestrel—ESR1—ATF-2 transcription factor network—CCND1—colon cancer	0.000767	0.00254	CbGpPWpGaD
Levonorgestrel—Oedema—Capecitabine—colon cancer	0.000766	0.00168	CcSEcCtD
Levonorgestrel—Infection—Capecitabine—colon cancer	0.000761	0.00167	CcSEcCtD
Levonorgestrel—ESR1—Plasma membrane estrogen receptor signaling—KRAS—colon cancer	0.00076	0.00252	CbGpPWpGaD
Levonorgestrel—Erythema multiforme—Methotrexate—colon cancer	0.000759	0.00166	CcSEcCtD
Levonorgestrel—Dizziness—Irinotecan—colon cancer	0.000757	0.00166	CcSEcCtD
Levonorgestrel—Shock—Capecitabine—colon cancer	0.000754	0.00165	CcSEcCtD
Levonorgestrel—Nervous system disorder—Capecitabine—colon cancer	0.000752	0.00165	CcSEcCtD
Levonorgestrel—Eye disorder—Methotrexate—colon cancer	0.000751	0.00164	CcSEcCtD
Levonorgestrel—Diarrhoea—Fluorouracil—colon cancer	0.00075	0.00164	CcSEcCtD
Levonorgestrel—ESR1—Aryl Hydrocarbon Receptor—MYC—colon cancer	0.00075	0.00249	CbGpPWpGaD
Levonorgestrel—Vomiting—Vincristine—colon cancer	0.000748	0.00164	CcSEcCtD
Levonorgestrel—AR—Regulation of nuclear SMAD2/3 signaling—CDKN1A—colon cancer	0.000747	0.00248	CbGpPWpGaD
Levonorgestrel—Cardiac disorder—Methotrexate—colon cancer	0.000745	0.00163	CcSEcCtD
Levonorgestrel—Skin disorder—Capecitabine—colon cancer	0.000745	0.00163	CcSEcCtD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—BAX—colon cancer	0.000744	0.00247	CbGpPWpGaD
Levonorgestrel—Rash—Vincristine—colon cancer	0.000741	0.00162	CcSEcCtD
Levonorgestrel—Hyperhidrosis—Capecitabine—colon cancer	0.000741	0.00162	CcSEcCtD
Levonorgestrel—Dermatitis—Vincristine—colon cancer	0.000741	0.00162	CcSEcCtD
Levonorgestrel—Headache—Vincristine—colon cancer	0.000737	0.00161	CcSEcCtD
Levonorgestrel—ESR1—Aryl Hydrocarbon Receptor—EGFR—colon cancer	0.000734	0.00244	CbGpPWpGaD
Levonorgestrel—Anorexia—Capecitabine—colon cancer	0.000731	0.0016	CcSEcCtD
Levonorgestrel—Vomiting—Irinotecan—colon cancer	0.000728	0.00159	CcSEcCtD
Levonorgestrel—Immune system disorder—Methotrexate—colon cancer	0.000725	0.00159	CcSEcCtD
Levonorgestrel—Dizziness—Fluorouracil—colon cancer	0.000725	0.00159	CcSEcCtD
Levonorgestrel—Mediastinal disorder—Methotrexate—colon cancer	0.000724	0.00158	CcSEcCtD
Levonorgestrel—Rash—Irinotecan—colon cancer	0.000722	0.00158	CcSEcCtD
Levonorgestrel—Dermatitis—Irinotecan—colon cancer	0.000721	0.00158	CcSEcCtD
Levonorgestrel—ESR1—Validated nuclear estrogen receptor alpha network—CCND1—colon cancer	0.000718	0.00238	CbGpPWpGaD
Levonorgestrel—AR—Regulation of nuclear beta catenin signaling and target gene transcription—EP300—colon cancer	0.000718	0.00238	CbGpPWpGaD
Levonorgestrel—Headache—Irinotecan—colon cancer	0.000717	0.00157	CcSEcCtD
Levonorgestrel—AR—Androgen receptor signaling pathway—CCND1—colon cancer	0.000716	0.00238	CbGpPWpGaD
Levonorgestrel—SRD5A1—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	0.000712	0.00236	CbGpPWpGaD
Levonorgestrel—AR—Regulation of nuclear SMAD2/3 signaling—EP300—colon cancer	0.000711	0.00236	CbGpPWpGaD
Levonorgestrel—Alopecia—Methotrexate—colon cancer	0.00071	0.00155	CcSEcCtD
Levonorgestrel—AR—Androgen receptor signaling pathway—CTNNB1—colon cancer	0.000709	0.00235	CbGpPWpGaD
Levonorgestrel—ESR1—ATF-2 transcription factor network—EP300—colon cancer	0.000706	0.00234	CbGpPWpGaD
Levonorgestrel—Mental disorder—Methotrexate—colon cancer	0.000704	0.00154	CcSEcCtD
Levonorgestrel—Malnutrition—Methotrexate—colon cancer	0.000699	0.00153	CcSEcCtD
Levonorgestrel—Erythema—Methotrexate—colon cancer	0.000699	0.00153	CcSEcCtD
Levonorgestrel—Nausea—Vincristine—colon cancer	0.000699	0.00153	CcSEcCtD
Levonorgestrel—ESR1—Plasma membrane estrogen receptor signaling—PIK3CA—colon cancer	0.000698	0.00232	CbGpPWpGaD
Levonorgestrel—Musculoskeletal discomfort—Capecitabine—colon cancer	0.000698	0.00153	CcSEcCtD
Levonorgestrel—Vomiting—Fluorouracil—colon cancer	0.000697	0.00153	CcSEcCtD
Levonorgestrel—ESR1—Aryl Hydrocarbon Receptor—KRAS—colon cancer	0.000693	0.0023	CbGpPWpGaD
Levonorgestrel—Insomnia—Capecitabine—colon cancer	0.000693	0.00152	CcSEcCtD
Levonorgestrel—AR—Androgen receptor signaling pathway—CDKN1A—colon cancer	0.000693	0.0023	CbGpPWpGaD
Levonorgestrel—Rash—Fluorouracil—colon cancer	0.000692	0.00151	CcSEcCtD
Levonorgestrel—ESR1—Integrated Breast Cancer Pathway—BAX—colon cancer	0.000692	0.0023	CbGpPWpGaD
Levonorgestrel—Dermatitis—Fluorouracil—colon cancer	0.000691	0.00151	CcSEcCtD
Levonorgestrel—Headache—Fluorouracil—colon cancer	0.000687	0.0015	CcSEcCtD
Levonorgestrel—ESR1—Regulation of Telomerase—CCND1—colon cancer	0.000684	0.00227	CbGpPWpGaD
Levonorgestrel—Dyspnoea—Capecitabine—colon cancer	0.000683	0.0015	CcSEcCtD
Levonorgestrel—Nausea—Irinotecan—colon cancer	0.00068	0.00149	CcSEcCtD
Levonorgestrel—Back pain—Methotrexate—colon cancer	0.000676	0.00148	CcSEcCtD
Levonorgestrel—Dyspepsia—Capecitabine—colon cancer	0.000675	0.00148	CcSEcCtD
Levonorgestrel—ESR1—AP-1 transcription factor network—CCND1—colon cancer	0.000669	0.00222	CbGpPWpGaD
Levonorgestrel—Decreased appetite—Capecitabine—colon cancer	0.000666	0.00146	CcSEcCtD
Levonorgestrel—ESR1—AP-1 transcription factor network—CTNNB1—colon cancer	0.000662	0.0022	CbGpPWpGaD
Levonorgestrel—Gastrointestinal disorder—Capecitabine—colon cancer	0.000662	0.00145	CcSEcCtD
Levonorgestrel—ESR1—Validated nuclear estrogen receptor alpha network—EP300—colon cancer	0.000661	0.00219	CbGpPWpGaD
Levonorgestrel—Fatigue—Capecitabine—colon cancer	0.000661	0.00145	CcSEcCtD
Levonorgestrel—AR—Androgen receptor signaling pathway—EP300—colon cancer	0.000659	0.00219	CbGpPWpGaD
Levonorgestrel—Constipation—Capecitabine—colon cancer	0.000655	0.00143	CcSEcCtD
Levonorgestrel—Pain—Capecitabine—colon cancer	0.000655	0.00143	CcSEcCtD
Levonorgestrel—Nausea—Fluorouracil—colon cancer	0.000652	0.00143	CcSEcCtD
Levonorgestrel—ESR1—LKB1 signaling events—TP53—colon cancer	0.00065	0.00216	CbGpPWpGaD
Levonorgestrel—ESR1—Plasma membrane estrogen receptor signaling—HRAS—colon cancer	0.000646	0.00214	CbGpPWpGaD
Levonorgestrel—Anaemia—Methotrexate—colon cancer	0.000646	0.00141	CcSEcCtD
Levonorgestrel—PGR—Signaling Pathways—DLC1—colon cancer	0.000646	0.00214	CbGpPWpGaD
Levonorgestrel—AR—Integrated Breast Cancer Pathway—BRAF—colon cancer	0.000643	0.00213	CbGpPWpGaD
Levonorgestrel—AR—Androgen receptor signaling pathway—SRC—colon cancer	0.000641	0.00213	CbGpPWpGaD
Levonorgestrel—ESR1—Leptin signaling pathway—CCND1—colon cancer	0.000633	0.0021	CbGpPWpGaD
Levonorgestrel—AR—Integrated Breast Cancer Pathway—CDH1—colon cancer	0.00063	0.00209	CbGpPWpGaD
Levonorgestrel—Vertigo—Methotrexate—colon cancer	0.000628	0.00137	CcSEcCtD
Levonorgestrel—Gastrointestinal pain—Capecitabine—colon cancer	0.000627	0.00137	CcSEcCtD
Levonorgestrel—AR—Generic Transcription Pathway—HNF4A—colon cancer	0.000626	0.00208	CbGpPWpGaD
Levonorgestrel—AR—Regulation of nuclear beta catenin signaling and target gene transcription—MYC—colon cancer	0.000626	0.00208	CbGpPWpGaD
Levonorgestrel—AR—Regulation of nuclear SMAD2/3 signaling—MYC—colon cancer	0.00062	0.00206	CbGpPWpGaD
Levonorgestrel—ESR1—AP-1 transcription factor network—EP300—colon cancer	0.000615	0.00204	CbGpPWpGaD
Levonorgestrel—Cough—Methotrexate—colon cancer	0.00061	0.00134	CcSEcCtD
Levonorgestrel—Urticaria—Capecitabine—colon cancer	0.000609	0.00133	CcSEcCtD
Levonorgestrel—PGR—Signaling Pathways—LGR5—colon cancer	0.000607	0.00202	CbGpPWpGaD
Levonorgestrel—Abdominal pain—Capecitabine—colon cancer	0.000606	0.00133	CcSEcCtD
Levonorgestrel—Body temperature increased—Capecitabine—colon cancer	0.000606	0.00133	CcSEcCtD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—ABCB1—colon cancer	0.000606	0.00201	CbGpPWpGaD
Levonorgestrel—Myalgia—Methotrexate—colon cancer	0.000595	0.0013	CcSEcCtD
Levonorgestrel—Chest pain—Methotrexate—colon cancer	0.000595	0.0013	CcSEcCtD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—TYMS—colon cancer	0.000595	0.00197	CbGpPWpGaD
Levonorgestrel—PGR—Signaling by ERBB4—CDKN1A—colon cancer	0.000593	0.00197	CbGpPWpGaD
Levonorgestrel—SRD5A1—Metabolism of lipids and lipoproteins—EP300—colon cancer	0.000592	0.00197	CbGpPWpGaD
Levonorgestrel—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—colon cancer	0.000591	0.00129	CcSEcCtD
Levonorgestrel—ESR1—Aryl Hydrocarbon Receptor—HRAS—colon cancer	0.000589	0.00196	CbGpPWpGaD
Levonorgestrel—Discomfort—Methotrexate—colon cancer	0.000588	0.00129	CcSEcCtD
Levonorgestrel—SRD5A1—Metabolism—ABCB1—colon cancer	0.000579	0.00192	CbGpPWpGaD
Levonorgestrel—ESR1—Validated nuclear estrogen receptor alpha network—MYC—colon cancer	0.000576	0.00191	CbGpPWpGaD
Levonorgestrel—ESR1—Regulation of nuclear SMAD2/3 signaling—CDKN1A—colon cancer	0.000576	0.00191	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—BAX—colon cancer	0.000573	0.0019	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling by ERBB4—FGFR3—colon cancer	0.000571	0.00189	CbGpPWpGaD
Levonorgestrel—ESR1—Plasma membrane estrogen receptor signaling—AKT1—colon cancer	0.000571	0.00189	CbGpPWpGaD
Levonorgestrel—SRD5A1—Metabolism—TYMS—colon cancer	0.000569	0.00189	CbGpPWpGaD
Levonorgestrel—Infection—Methotrexate—colon cancer	0.000567	0.00124	CcSEcCtD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—APC—colon cancer	0.000567	0.00188	CbGpPWpGaD
Levonorgestrel—ESR1—Leptin signaling pathway—SRC—colon cancer	0.000566	0.00188	CbGpPWpGaD
Levonorgestrel—Hypersensitivity—Capecitabine—colon cancer	0.000565	0.00124	CcSEcCtD
Levonorgestrel—AR—Androgen receptor signaling pathway—EGFR—colon cancer	0.000562	0.00187	CbGpPWpGaD
Levonorgestrel—Nervous system disorder—Methotrexate—colon cancer	0.00056	0.00122	CcSEcCtD
Levonorgestrel—Skin disorder—Methotrexate—colon cancer	0.000554	0.00121	CcSEcCtD
Levonorgestrel—CYP19A1—Integrated Breast Cancer Pathway—BRAF—colon cancer	0.000553	0.00184	CbGpPWpGaD
Levonorgestrel—Hyperhidrosis—Methotrexate—colon cancer	0.000552	0.00121	CcSEcCtD
Levonorgestrel—Asthenia—Capecitabine—colon cancer	0.00055	0.0012	CcSEcCtD
Levonorgestrel—ESR1—Regulation of Telomerase—MYC—colon cancer	0.000549	0.00182	CbGpPWpGaD
Levonorgestrel—ESR1—Regulation of nuclear SMAD2/3 signaling—EP300—colon cancer	0.000548	0.00182	CbGpPWpGaD
Levonorgestrel—ESR1—Regulation of Telomerase—TGFB1—colon cancer	0.000548	0.00182	CbGpPWpGaD
Levonorgestrel—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—colon cancer	0.000546	0.00181	CbGpPWpGaD
Levonorgestrel—Anorexia—Methotrexate—colon cancer	0.000544	0.00119	CcSEcCtD
Levonorgestrel—Pruritus—Capecitabine—colon cancer	0.000542	0.00119	CcSEcCtD
Levonorgestrel—CYP19A1—Integrated Breast Cancer Pathway—CDH1—colon cancer	0.000542	0.0018	CbGpPWpGaD
Levonorgestrel—AR—Coregulation of Androgen receptor activity—AKT1—colon cancer	0.000539	0.00179	CbGpPWpGaD
Levonorgestrel—ESR1—Regulation of Telomerase—EGFR—colon cancer	0.000537	0.00178	CbGpPWpGaD
Levonorgestrel—ESR1—AP-1 transcription factor network—MYC—colon cancer	0.000536	0.00178	CbGpPWpGaD
Levonorgestrel—ESR1—AP-1 transcription factor network—TGFB1—colon cancer	0.000535	0.00178	CbGpPWpGaD
Levonorgestrel—PGR—Signaling by ERBB4—NRAS—colon cancer	0.000528	0.00175	CbGpPWpGaD
Levonorgestrel—Diarrhoea—Capecitabine—colon cancer	0.000524	0.00115	CcSEcCtD
Levonorgestrel—Musculoskeletal discomfort—Methotrexate—colon cancer	0.00052	0.00114	CcSEcCtD
Levonorgestrel—Insomnia—Methotrexate—colon cancer	0.000516	0.00113	CcSEcCtD
Levonorgestrel—Dyspnoea—Methotrexate—colon cancer	0.000509	0.00111	CcSEcCtD
Levonorgestrel—Somnolence—Methotrexate—colon cancer	0.000507	0.00111	CcSEcCtD
Levonorgestrel—Dizziness—Capecitabine—colon cancer	0.000507	0.00111	CcSEcCtD
Levonorgestrel—Dyspepsia—Methotrexate—colon cancer	0.000502	0.0011	CcSEcCtD
Levonorgestrel—Decreased appetite—Methotrexate—colon cancer	0.000496	0.00109	CcSEcCtD
Levonorgestrel—ESR1—Integrated Breast Cancer Pathway—BRAF—colon cancer	0.000495	0.00164	CbGpPWpGaD
Levonorgestrel—Gastrointestinal disorder—Methotrexate—colon cancer	0.000493	0.00108	CcSEcCtD
Levonorgestrel—Fatigue—Methotrexate—colon cancer	0.000492	0.00108	CcSEcCtD
Levonorgestrel—Pain—Methotrexate—colon cancer	0.000488	0.00107	CcSEcCtD
Levonorgestrel—Vomiting—Capecitabine—colon cancer	0.000487	0.00107	CcSEcCtD
Levonorgestrel—ESR1—Integrated Breast Cancer Pathway—CDH1—colon cancer	0.000485	0.00161	CbGpPWpGaD
Levonorgestrel—Rash—Capecitabine—colon cancer	0.000483	0.00106	CcSEcCtD
Levonorgestrel—Dermatitis—Capecitabine—colon cancer	0.000483	0.00106	CcSEcCtD
Levonorgestrel—ESR1—Generic Transcription Pathway—HNF4A—colon cancer	0.000482	0.0016	CbGpPWpGaD
Levonorgestrel—AR—Integrated Breast Cancer Pathway—CASP3—colon cancer	0.000482	0.0016	CbGpPWpGaD
Levonorgestrel—PGR—Signaling by ERBB4—EGFR—colon cancer	0.000481	0.0016	CbGpPWpGaD
Levonorgestrel—Headache—Capecitabine—colon cancer	0.00048	0.00105	CcSEcCtD
Levonorgestrel—ESR1—Regulation of nuclear SMAD2/3 signaling—MYC—colon cancer	0.000477	0.00158	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—CHST5—colon cancer	0.000476	0.00158	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—ODC1—colon cancer	0.000476	0.00158	CbGpPWpGaD
Levonorgestrel—AR—SIDS Susceptibility Pathways—CASP3—colon cancer	0.00047	0.00156	CbGpPWpGaD
Levonorgestrel—AR—Integrated Breast Cancer Pathway—CCND1—colon cancer	0.000469	0.00156	CbGpPWpGaD
Levonorgestrel—Gastrointestinal pain—Methotrexate—colon cancer	0.000467	0.00102	CcSEcCtD
Levonorgestrel—AR—Integrated Breast Cancer Pathway—CTNNB1—colon cancer	0.000465	0.00154	CbGpPWpGaD
Levonorgestrel—Nausea—Capecitabine—colon cancer	0.000455	0.000997	CcSEcCtD
Levonorgestrel—PGR—Signaling by ERBB4—KRAS—colon cancer	0.000454	0.00151	CbGpPWpGaD
Levonorgestrel—Urticaria—Methotrexate—colon cancer	0.000453	0.000992	CcSEcCtD
Levonorgestrel—AR—SIDS Susceptibility Pathways—CTNNB1—colon cancer	0.000453	0.0015	CbGpPWpGaD
Levonorgestrel—Abdominal pain—Methotrexate—colon cancer	0.000451	0.000987	CcSEcCtD
Levonorgestrel—Body temperature increased—Methotrexate—colon cancer	0.000451	0.000987	CcSEcCtD
Levonorgestrel—ESR1—AP-1 transcription factor network—TP53—colon cancer	0.00044	0.00146	CbGpPWpGaD
Levonorgestrel—SRD5A1—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	0.000438	0.00145	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—APC—colon cancer	0.000437	0.00145	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—AXIN2—colon cancer	0.000436	0.00145	CbGpPWpGaD
Levonorgestrel—AR—Integrated Breast Cancer Pathway—EP300—colon cancer	0.000432	0.00143	CbGpPWpGaD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—PTGS2—colon cancer	0.00043	0.00143	CbGpPWpGaD
Levonorgestrel—AR—Regulation of nuclear SMAD2/3 signaling—AKT1—colon cancer	0.00043	0.00143	CbGpPWpGaD
Levonorgestrel—AR—SIDS Susceptibility Pathways—EP300—colon cancer	0.000421	0.0014	CbGpPWpGaD
Levonorgestrel—Hypersensitivity—Methotrexate—colon cancer	0.00042	0.00092	CcSEcCtD
Levonorgestrel—PGR—Signaling by ERBB4—PIK3CA—colon cancer	0.000417	0.00138	CbGpPWpGaD
Levonorgestrel—CYP19A1—Integrated Breast Cancer Pathway—CASP3—colon cancer	0.000415	0.00138	CbGpPWpGaD
Levonorgestrel—Asthenia—Methotrexate—colon cancer	0.000409	0.000896	CcSEcCtD
Levonorgestrel—AR—Integrated Breast Cancer Pathway—VEGFA—colon cancer	0.000409	0.00136	CbGpPWpGaD
Levonorgestrel—CYP19A1—Integrated Breast Cancer Pathway—CCND1—colon cancer	0.000404	0.00134	CbGpPWpGaD
Levonorgestrel—Pruritus—Methotrexate—colon cancer	0.000404	0.000884	CcSEcCtD
Levonorgestrel—SRD5A1—Metabolism—PPARG—colon cancer	0.000403	0.00134	CbGpPWpGaD
Levonorgestrel—CYP19A1—Integrated Breast Cancer Pathway—CTNNB1—colon cancer	0.0004	0.00133	CbGpPWpGaD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—CASP3—colon cancer	0.000399	0.00133	CbGpPWpGaD
Levonorgestrel—ESR1—Leptin signaling pathway—HRAS—colon cancer	0.000399	0.00132	CbGpPWpGaD
Levonorgestrel—AR—SIDS Susceptibility Pathways—VEGFA—colon cancer	0.000399	0.00132	CbGpPWpGaD
Levonorgestrel—AR—Androgen receptor signaling pathway—AKT1—colon cancer	0.000398	0.00132	CbGpPWpGaD
Levonorgestrel—PGR—Gene Expression—HNF4A—colon cancer	0.000396	0.00131	CbGpPWpGaD
Levonorgestrel—Diarrhoea—Methotrexate—colon cancer	0.00039	0.000855	CcSEcCtD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—CCND1—colon cancer	0.000389	0.00129	CbGpPWpGaD
Levonorgestrel—PGR—Signaling by ERBB4—HRAS—colon cancer	0.000386	0.00128	CbGpPWpGaD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—CTNNB1—colon cancer	0.000385	0.00128	CbGpPWpGaD
Levonorgestrel—ESR1—Regulation of Telomerase—AKT1—colon cancer	0.000381	0.00126	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—DLC1—colon cancer	0.000379	0.00126	CbGpPWpGaD
Levonorgestrel—Dizziness—Methotrexate—colon cancer	0.000377	0.000826	CcSEcCtD
Levonorgestrel—AR—Integrated Breast Cancer Pathway—MYC—colon cancer	0.000376	0.00125	CbGpPWpGaD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—CDKN1A—colon cancer	0.000376	0.00125	CbGpPWpGaD
Levonorgestrel—CYP19A1—Integrated Breast Cancer Pathway—EP300—colon cancer	0.000372	0.00123	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Breast Cancer Pathway—CASP3—colon cancer	0.000371	0.00123	CbGpPWpGaD
Levonorgestrel—AR—Integrated Breast Cancer Pathway—EGFR—colon cancer	0.000368	0.00122	CbGpPWpGaD
Levonorgestrel—Vomiting—Methotrexate—colon cancer	0.000363	0.000794	CcSEcCtD
Levonorgestrel—ESR1—Integrated Breast Cancer Pathway—CCND1—colon cancer	0.000361	0.0012	CbGpPWpGaD
Levonorgestrel—Rash—Methotrexate—colon cancer	0.00036	0.000788	CcSEcCtD
Levonorgestrel—Dermatitis—Methotrexate—colon cancer	0.000359	0.000787	CcSEcCtD
Levonorgestrel—ESR1—Integrated Breast Cancer Pathway—CTNNB1—colon cancer	0.000358	0.00119	CbGpPWpGaD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—EP300—colon cancer	0.000358	0.00119	CbGpPWpGaD
Levonorgestrel—Headache—Methotrexate—colon cancer	0.000357	0.000782	CcSEcCtD
Levonorgestrel—PGR—Generic Transcription Pathway—PPARG—colon cancer	0.000357	0.00118	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—LGR5—colon cancer	0.000356	0.00118	CbGpPWpGaD
Levonorgestrel—CYP19A1—Integrated Breast Cancer Pathway—VEGFA—colon cancer	0.000352	0.00117	CbGpPWpGaD
Levonorgestrel—ESR1—Leptin signaling pathway—AKT1—colon cancer	0.000352	0.00117	CbGpPWpGaD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—SRC—colon cancer	0.000348	0.00116	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling by ERBB4—CDKN1A—colon cancer	0.000348	0.00115	CbGpPWpGaD
Levonorgestrel—AR—Integrated Breast Cancer Pathway—KRAS—colon cancer	0.000348	0.00115	CbGpPWpGaD
Levonorgestrel—PGR—Signaling by ERBB4—AKT1—colon cancer	0.000341	0.00113	CbGpPWpGaD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—VEGFA—colon cancer	0.000339	0.00113	CbGpPWpGaD
Levonorgestrel—Nausea—Methotrexate—colon cancer	0.000339	0.000742	CcSEcCtD
Levonorgestrel—ESR1—Integrated Breast Cancer Pathway—EP300—colon cancer	0.000333	0.0011	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—PTGS2—colon cancer	0.000332	0.0011	CbGpPWpGaD
Levonorgestrel—ESR1—Regulation of nuclear SMAD2/3 signaling—AKT1—colon cancer	0.000331	0.0011	CbGpPWpGaD
Levonorgestrel—CYP19A1—Integrated Breast Cancer Pathway—MYC—colon cancer	0.000324	0.00107	CbGpPWpGaD
Levonorgestrel—Ethinyl Estradiol—ABCB1—colon cancer	0.000321	0.267	CrCbGaD
Levonorgestrel—SRD5A1—Metabolism—PTGS2—colon cancer	0.000317	0.00105	CbGpPWpGaD
Levonorgestrel—CYP19A1—Integrated Breast Cancer Pathway—EGFR—colon cancer	0.000317	0.00105	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Breast Cancer Pathway—VEGFA—colon cancer	0.000315	0.00105	CbGpPWpGaD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—MYC—colon cancer	0.000312	0.00104	CbGpPWpGaD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—TGFB1—colon cancer	0.000311	0.00103	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling by ERBB4—NRAS—colon cancer	0.00031	0.00103	CbGpPWpGaD
Levonorgestrel—AR—Integrated Breast Cancer Pathway—TP53—colon cancer	0.000309	0.00103	CbGpPWpGaD
Levonorgestrel—Norethindrone—ABCB1—colon cancer	0.000309	0.257	CrCbGaD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—CASP3—colon cancer	0.000308	0.00102	CbGpPWpGaD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—EGFR—colon cancer	0.000305	0.00101	CbGpPWpGaD
Levonorgestrel—AR—Gene Expression—HNF4A—colon cancer	0.000301	0.001	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—CCND1—colon cancer	0.0003	0.000994	CbGpPWpGaD
Levonorgestrel—CYP19A1—Integrated Breast Cancer Pathway—KRAS—colon cancer	0.000299	0.000993	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—CTNNB1—colon cancer	0.000297	0.000984	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Breast Cancer Pathway—MYC—colon cancer	0.00029	0.000962	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—CDKN1A—colon cancer	0.00029	0.000962	CbGpPWpGaD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—KRAS—colon cancer	0.000288	0.000956	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Breast Cancer Pathway—EGFR—colon cancer	0.000284	0.000941	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling by ERBB4—EGFR—colon cancer	0.000282	0.000936	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—EP300—colon cancer	0.000276	0.000915	CbGpPWpGaD
Levonorgestrel—AR—Generic Transcription Pathway—PPARG—colon cancer	0.000272	0.000902	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—SRC—colon cancer	0.000268	0.00089	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Breast Cancer Pathway—KRAS—colon cancer	0.000268	0.000889	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling by ERBB4—KRAS—colon cancer	0.000267	0.000884	CbGpPWpGaD
Levonorgestrel—CYP19A1—Integrated Breast Cancer Pathway—TP53—colon cancer	0.000266	0.000883	CbGpPWpGaD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—PIK3CA—colon cancer	0.000265	0.000879	CbGpPWpGaD
Levonorgestrel—SRD5A1—Metabolism—EP300—colon cancer	0.000264	0.000875	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—VEGFA—colon cancer	0.000261	0.000867	CbGpPWpGaD
Levonorgestrel—AR—Integrated Breast Cancer Pathway—AKT1—colon cancer	0.000261	0.000866	CbGpPWpGaD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—TP53—colon cancer	0.000256	0.00085	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—AXIN2—colon cancer	0.000256	0.00085	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling by ERBB4—PIK3CA—colon cancer	0.000245	0.000813	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—MYC—colon cancer	0.00024	0.000797	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—TGFB1—colon cancer	0.00024	0.000795	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Breast Cancer Pathway—TP53—colon cancer	0.000238	0.00079	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—EGFR—colon cancer	0.000235	0.00078	CbGpPWpGaD
Levonorgestrel—ESR1—Gene Expression—HNF4A—colon cancer	0.000232	0.00077	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—CA7—colon cancer	0.000229	0.000761	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling by ERBB4—HRAS—colon cancer	0.000227	0.000752	CbGpPWpGaD
Levonorgestrel—CYP19A1—Integrated Breast Cancer Pathway—AKT1—colon cancer	0.000225	0.000745	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—KRAS—colon cancer	0.000222	0.000737	CbGpPWpGaD
Levonorgestrel—Hydrocortisone—ABCB1—colon cancer	0.000221	0.184	CrCbGaD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—AKT1—colon cancer	0.000216	0.000718	CbGpPWpGaD
Levonorgestrel—ESR1—Generic Transcription Pathway—PPARG—colon cancer	0.000209	0.000695	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—PIK3CA—colon cancer	0.000204	0.000677	CbGpPWpGaD
Levonorgestrel—PGR—Generic Transcription Pathway—MYC—colon cancer	0.000203	0.000675	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Breast Cancer Pathway—AKT1—colon cancer	0.000201	0.000667	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling by ERBB4—AKT1—colon cancer	0.0002	0.000664	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—TP53—colon cancer	0.000197	0.000655	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism of lipids and lipoproteins—PPARG—colon cancer	0.000197	0.000652	CbGpPWpGaD
Levonorgestrel—SRD5A1—Metabolism—PIK3CA—colon cancer	0.000195	0.000647	CbGpPWpGaD
Levonorgestrel—Progesterone—ABCB1—colon cancer	0.00018	0.15	CrCbGaD
Levonorgestrel—PGR—Gene Expression—PPARG—colon cancer	0.000172	0.00057	CbGpPWpGaD
Levonorgestrel—Testosterone—ABCB1—colon cancer	0.00017	0.142	CrCbGaD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—AKT1—colon cancer	0.000167	0.000553	CbGpPWpGaD
Levonorgestrel—SRD5A1—Metabolism—AKT1—colon cancer	0.000159	0.000529	CbGpPWpGaD
Levonorgestrel—AR—Generic Transcription Pathway—MYC—colon cancer	0.000155	0.000514	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	0.000155	0.000513	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—CHST5—colon cancer	0.000139	0.000461	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—ODC1—colon cancer	0.000139	0.000461	CbGpPWpGaD
Levonorgestrel—AR—Gene Expression—PPARG—colon cancer	0.000131	0.000434	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism of lipids and lipoproteins—EP300—colon cancer	0.000129	0.000427	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—FGFR3—colon cancer	0.000126	0.000418	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—ABCB1—colon cancer	0.000126	0.000418	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—TYMS—colon cancer	0.000124	0.00041	CbGpPWpGaD
Levonorgestrel—ESR1—Generic Transcription Pathway—MYC—colon cancer	0.000119	0.000396	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—APC—colon cancer	0.000116	0.000384	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—BRAF—colon cancer	0.000109	0.000361	CbGpPWpGaD
Levonorgestrel—ESR1—Gene Expression—PPARG—colon cancer	0.000101	0.000334	CbGpPWpGaD
Levonorgestrel—PGR—Gene Expression—MYC—colon cancer	9.79e-05	0.000325	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	9.51e-05	0.000316	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—PPARG—colon cancer	8.75e-05	0.000291	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—CASP3—colon cancer	8.15e-05	0.000271	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—CCND1—colon cancer	7.94e-05	0.000263	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—CTNNB1—colon cancer	7.86e-05	0.000261	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—CDKN1A—colon cancer	7.68e-05	0.000255	CbGpPWpGaD
Levonorgestrel—AR—Gene Expression—MYC—colon cancer	7.46e-05	0.000248	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—FGFR3—colon cancer	7.4e-05	0.000245	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—EP300—colon cancer	7.31e-05	0.000242	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—SRC—colon cancer	7.1e-05	0.000236	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—VEGFA—colon cancer	6.92e-05	0.00023	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—PTGS2—colon cancer	6.89e-05	0.000229	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—NRAS—colon cancer	6.83e-05	0.000227	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—APC—colon cancer	6.79e-05	0.000225	CbGpPWpGaD
Levonorgestrel—PGR—Gene Expression—AKT1—colon cancer	6.79e-05	0.000225	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—BRAF—colon cancer	6.38e-05	0.000212	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—MYC—colon cancer	6.37e-05	0.000211	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—TGFB1—colon cancer	6.35e-05	0.000211	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—EGFR—colon cancer	6.23e-05	0.000207	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—KRAS—colon cancer	5.88e-05	0.000195	CbGpPWpGaD
Levonorgestrel—ESR1—Gene Expression—MYC—colon cancer	5.75e-05	0.000191	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—EP300—colon cancer	5.73e-05	0.00019	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—PIK3CA—colon cancer	5.4e-05	0.000179	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—TP53—colon cancer	5.23e-05	0.000173	CbGpPWpGaD
Levonorgestrel—AR—Gene Expression—AKT1—colon cancer	5.17e-05	0.000172	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—HRAS—colon cancer	5e-05	0.000166	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—CASP3—colon cancer	4.79e-05	0.000159	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—CCND1—colon cancer	4.66e-05	0.000155	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—CTNNB1—colon cancer	4.61e-05	0.000153	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—CDKN1A—colon cancer	4.51e-05	0.00015	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—AKT1—colon cancer	4.41e-05	0.000147	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—EP300—colon cancer	4.29e-05	0.000142	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—PIK3CA—colon cancer	4.24e-05	0.000141	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—SRC—colon cancer	4.17e-05	0.000138	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—VEGFA—colon cancer	4.06e-05	0.000135	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—NRAS—colon cancer	4.01e-05	0.000133	CbGpPWpGaD
Levonorgestrel—ESR1—Gene Expression—AKT1—colon cancer	3.98e-05	0.000132	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—MYC—colon cancer	3.74e-05	0.000124	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—TGFB1—colon cancer	3.73e-05	0.000124	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—ABCB1—colon cancer	3.67e-05	0.000122	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—EGFR—colon cancer	3.65e-05	0.000121	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—TYMS—colon cancer	3.61e-05	0.00012	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—AKT1—colon cancer	3.46e-05	0.000115	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—KRAS—colon cancer	3.45e-05	0.000115	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—PIK3CA—colon cancer	3.17e-05	0.000105	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—TP53—colon cancer	3.07e-05	0.000102	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—HRAS—colon cancer	2.93e-05	9.74e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—AKT1—colon cancer	2.59e-05	8.6e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—PPARG—colon cancer	2.55e-05	8.48e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—PTGS2—colon cancer	2.01e-05	6.67e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—EP300—colon cancer	1.67e-05	5.55e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—PIK3CA—colon cancer	1.24e-05	4.1e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—AKT1—colon cancer	1.01e-05	3.35e-05	CbGpPWpGaD
